Impact of increased erythropoietin receptor expression and elevated serum erythropoietin levels on clinicopathological features and prognosis in renal cell carcinoma

Experimental and Therapeutic Medicine

Volumn 3, Issue 6, 2012, Pages 937-944

  Ito, Keiichi ^a   Yoshii, Hidehiko ^a   Asano, Takako ^a   Horiguchi, Akio ^a   Sumitomo, Makoto ^a   Hayakawa, Masamichi ^a   Asano, Tomohiko ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Erythropoietin; Erythropoietin receptor; Microvascular invasion; Prognosis; Renal cell carcinoma

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STAINING; TUMOR GROWTH;

EID: 84859463545     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.513     Document Type: Article

References (20)

1. Da Silva JL, Lacombe C, Bruneval P, Casadevall N, Leporrier M, Camilleri JP, Bariety J, Tambourin P and Varet B: Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 75: 577-582, 1990.
2. Westenfelder C and Baranowski RL: Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58: 647-657, 2000.
3. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP and Dewhirst MW: Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339, 2006.
4. Ljungberg B, Rasmuson T and Grankvist K: Erythropoietin in renal cell carcinoma: evaluation of its usefulness as a tumor marker. Eur Urol 21: 160-163, 1992.
5. Michael A, Politi E, Havranek E, Corbishley C, Karapanagiotou L, Anderson C, Relph K, Syrigos KN and Pandha H: Prognostic significance of erythropoietin expression in human renal cell carcinoma. BJU Int 100: 291-294, 2007.
6. Saintigny P, Besse B, Callard P, Vergnaud AC, Czernichow S, Colombat M, Girard P, Validire P, Breau JL, Bernaudin JF and Soria JC: Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res 13: 4825-4831, 2007.
7. Acs G, Xu X, Chu C, Acs P and Verma A: Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386, 2004.
8. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL and Grandis JR: Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24: 4442-4449, 2005.
9. Lester RD, Jo M, Campana WM and Gonias SL: Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem 280: 39273-39277, 2005.
10. Tilbrook PA, Colley SM, McCarthy DJ, Marais R and Klinken SP: Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells. Arch Biochem Biophys 396: 128-132, 2001.
11. Gong K, Zhang N, Zhang Z and Na Y: Coexpression of erythopoietin and erythopoietin receptor in sporadic clear cell renal cell carcinoma. Cancer Biol Ther 5: 582-585, 2006.
12. Papworth K, Bergh A, Grankvist K, Ljungberg B and Rasmuson T: Expression of erythropoietin and its receptor in human renal cell carcinoma. Tumour Biol 30: 86-92, 2009.
13. Ito K, Yoshii H, Asakuma J, Sato A, Horiguchi A, Sumitomo M, Hayakawa M and Asano T: Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens. Jpn J Clin Oncol 39: 588-594, 2009.
14. Horiguchi A, Asano T, Asakuma J, Asano T, Sumitomo M and Hayakawa M: Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma. J Urol 172: 718-722, 2004.
15. Sturiale A, Campo S, Crascì E, Coppolino G, Bolignano D, Grasso G and Buemi M: Erythropoietin and its lost receptor. Nephrol Dial Transplant 22: 1484-1485, 2007.
16. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T and Hayakawa M: Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62: 4176-4179, 2002.
17. Islam AH, Ehara T, Kato H, Hayama M, Kobayashi S, Igawa Y and Nishizawa O: Calponin h1 expression in renal tumor vessels: correlations with multiple pathological factors of renal cell carcinoma. J Urol 171: 1319-1323, 2004.
18. Ribatti D, Marzullo A, Nico B, Crivellato E, Ria R and Vacca A: Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 42: 246-250, 2003.
19. Vesey DA, Cheung C, Pat B, Endre Z, Gobé G and Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355, 2004.
20. Li J, Vesey DA, Johnson DW and Gobe G: Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 6: 1944-1950, 2007.